Abstract: Botulinum toxin is a therapeutic option in chronic migraine. No dose-finding studies have been conducted so far. Some authors maintain that one injection into the corrugator muscle will do.
INTRODUCTION
For years, Botulinum toxin (BTX) has been considered an option in the management of chronic migraine [1] . The data published represent contradictory results. Based on current research [2] [3] [4] , the intermediate approval for treatment of chronic migraine is obtained in USA and UK and expected in continental Europe. There is no evidence for a beneficial effect of BTX in patients with episodic migraine [5] .
Standardized doses and injection schemes have most commonly been used. A dose-finding study has not yet been conducted. In many studies high doses were preferred, without any justification. Some authors maintain that one injection into the corrugator muscle will suffice; surgical sectioning is recommended if there is response to treatment [6, 7] .
With this study we therefore wanted to elucidate whether or not a small dose of botulinum toxin injected at only two
EXCLUSION CRITERIA:
Participation in another clinical trial within the past 3 months Specific pain in neck/shoulder region in need of different specific treatment (i.e. acute nerve irritation with disk prolapse, manifest inflammatory processes etc.)
Contraindication of treatment with botulinum toxin (ascertained sensitivity to clostridial toxin or to one of the other ingredients and generalized disorders of muscular activity, e.g. myasthenia gravis or Lambert-Eaton syndrome)
Pregnancy or breastfeeding, inadequate or no contraception in women of childbearing age Serious concomitant illnesses involving the internal organs in particular, and systemic diseases and serious neurologic disorders Abuse of alcohol, drugs and narcotics Medication with anticoagulants and heparin preparation (topically applied heparin unguents excluded), thrombocyte aggregation inhibitors, aminoglycoside antibiotics, spectinomycin or muscle relaxants of the tubocurarine type
The patients gave their written consent to participate in the study. The study was also endorsed by the local Ethics Commission.
Pain reduction was the primary target parameter at any time of set examinations, as determined by the visual analog scale.
The changes in pertinent scores to rate pain and to assess the state of health (SF-McGill Pain Questionnaire, Northwick Park Neck Pain Questionnaire, IQOLA SF 36, SADP, OLBPDQ,) were defined as secondary target parameters. Additional focus was on undesired drug effects, the number and duration of headache attacks and adjuvant medication.
The statistical evaluation was done by SPSS (V.13). An injection was administered with 5 MU Onabotulinum toxin A (0.1 ml Botox®) /injection site vs. 0.1 ml 0.9% NaClsolution in crossover design into the corrugator muscle and the occipitalis muscle of the side affected -thus a total of 10 U Botox ® . Four months later, a reinjection was applied with the alternative injection scheme ( Table 1) . At the end of phase 2, the patients were offered free-of-charge further treatment with the true preparation.
RESULTS
Evaluated were 19 patients (PP), 45.2 ± 11.1 years old, 17 of them were females.
We found no clinically relevant or statistically significant differences regarding the target parameters in both injection intervals (for example: VAS pain intensity p=0.702), with a notable placebo effect ( Table 2) ; good or excellent improvement (TOQ) 36.8% after 6 weeks in the placebo group. BTX proved to be superior in merely two aspects. The pain quality "throbbing" (SF-MPQ SADP) was initially rated by 11 patients as very intense, after BTX only 4 of them claimed that this had not changed. As far as the perception of pain intensity (PPI) was concerned, 42.2% of the subjects described their pain as "limiting" or "horrible" before receiving the injection; this held true for 26.3% 6 weeks later, and for 21.1% after 4 months. In the placebo group, this initially pertained to 31.6%, after 6 weeks to 31.6% again, and after 4 months to 42.2%. 84.2% in the Onabotulinum toxin Agroup and 63.2% in the placebo group requested a reinjection upon completion of the study.
DISCUSSION
Meanwhile dozens of studies have been published on the efficacy of botulinum toxin in various pain syndromes. Noteworthy among them is the research done in the field of chronic headache; the results, however, are unfortunately rather contradictory [8] [9] [10] [11] .
Most of the open studies related positive results, whilst most of the controlled studies reported negative findings [8, 10, 12, 13] . The type of headache is certainly playing a key role; current findings corroborate the effect on chronic migraine rather than on tensiontype headache [10] . The criterion "chronic" proved to be decisive, meaning patients have headaches more than half of the time. Whereas good results had first and foremost been obtained for patients with chronic daily headache [9, 11, 14] , positive outcomes have in the mean time been verified in chronic migraine as well [2] [3] [4] .
By direct comparison with topiramate, a similar action was revealed in the presence of considerably less undesirable effects [15] . In another study BTX was as effective as amitriptyline [16] .
We set out to study the effect of injections at 2 sites unilaterally (in the corrugator and occipitalis muscle ipsilaterally) with a low dose of BTX (total 10 U Onabotulinum toxin A). This study hasn't been adequately powered, its validity is therefore limited. We terminated the inclusion of patients after not seeing any clinical improvement. A statistically reliable conclusion would have required a much larger group of patients.
There were no appreciable differences in both groups. One injection only administered to these two sites would thus qualify as inefficient. Of course, this also applies to one injection into the corrugator muscle alone. The surgical section of the corrugator muscle after the alleged response to a BTX injection must not be regarded as a therapeutic option for migraine [6, 7] .
In the assessment of effects we always distinguish strictly between episodic and chronic migraine. However, we are not dealing with 2 entities of disease. The classification is solely based on the time factor. We presently have no evidence that BTX is efficient in episodic migraine, but there is sufficient evidence as to its efficacy in chronic migraine. Of course, and by reversal conclusion, this doesn't mean that BTX won't work in episodic migraine. There is merely no statistical significance.
CONCLUSION
From the data published so far, the injection of BTX may be considered a promising approach in the management of chronic migraine. Optimum injection sites and appropriate doses, however, still need more exploration. One injection into the corrugator muscle alone must be considered as ineffective
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